Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 52, 5985-5990, November 1, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jerome, K. R.
Right arrow Articles by Finn, O. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jerome, K. R.
Right arrow Articles by Finn, O. J.

Expression of Tumor-associated Epitopes on Epstein-Barr Virus-immortalized B-Cells and Burkitt's Lymphomas Transfected with Epithelial Mucin Complementary DNA1

Keith R. Jerome, Dawen Bu and Olivera J. Finn2

Department of Immunology, Duke University Medical Center, Durham, North Carolina 27710 [K. R. J., O. J. F.]; and the Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260 [D. B., O. J. F.]

Mucins are among the best described human tumor-associated antigens. At least 73 tumor-reactive anti-mucin antibodies have been described; in addition, we have previously demonstrated the existence of tumor-specific cytotoxic T-lymphocyte epitopes on the mucin produced by breast and pancreatic tumors. To determine whether the appearance of tumor-associated mucin epitopes can be explained by altered post-translational modification of mucin in tumors, or whether the generation of these epitopes requires changes in the mucin gene itself, we studied four Burkitt's lymphomas and six Epstein-Barr virus-immortalized B-cell lines transfected with an expression construct containing the mucin complementary DNA. Transfected cell lines showed stable maintenance of the mucin gene, which comprises 20 or more tandem repeats of a 60-nucleotide sequence. Transfected cells expressed many tumor-associated mucin epitopes, suggesting that the changes in mucin synthesis seen in breast and pancreatic tumors are present in other malignant cell types as well. Furthermore, even though each cell line was transfected with the identical mucin construct, each expressed a different subset of tumor-associated mucin epitopes. This suggests that the specificity of these epitopes for tumors is not due to genetic alterations of the mucin gene in tumors. Incubating transfected cells with phenyl-N-acetyl-{alpha}-galactosaminide, an inhibitor of O-linked glycosylation, altered cell surface carbohydrate structures and resulted in increased expression of all tumor-associated epitopes, implicating incomplete glycosylation of mucin in the generation of these epitopes. These findings suggest that alterations in the posttranslational modification of normal gene products can result in the expression of novel epitopes. Furthermore, the ability to transfect cancer patients' Epstein-Barr virus-immortalized B-cell lines with mucin will provide an unlimited supply of autologous, mucin-bearing cells with which to study these patients' T-cell response to mucin.

1 This work was supported by NIH Grant R01-CA-56103 to O. J. F. and by NIH Training Grant 5-T32-CA-39930 to K. R. J.

2 To whom requests for reprints should be addressed, at W1143 Biomedical Science Tower, Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, PA 15261. O. J. F. is a member of the Pittsburgh Cancer Institute Immunology Program.

Received 4/17/92. Accepted 8/26/92.




This article has been cited by other articles:


Home page
Cancer Res.Home page
H. J. Wajchman, C. W. Pierce, V. A. Varma, M. M. Issa, J. Petros, and K. E. Dombrowski
Ex Vivo Expansion of CD8+CD56+ and CD8+CD56- Natural Killer T Cells Specific for MUC1 Mucin
Cancer Res., February 1, 2004; 64(3): 1171 - 1180.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. A. Chung, Y. Luo, M. O'Donnell, C. Rodriguez, W. Heber, S. Sharma, and H. R. Chang
Development and Preclinical Evaluation of a Bacillus Calmette-Guerin-MUC1-based Novel Breast Cancer Vaccine
Cancer Res., March 15, 2003; 63(6): 1280 - 1287.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Higashi, K. Fujioka, K. Denda-Nagai, S.-i. Hashimoto, S. Nagai, T. Sato, Y. Fujita, A. Morikawa, M. Tsuiji, M. Miyata-Takeuchi, et al.
The Macrophage C-type Lectin Specific for Galactose/N-Acetylgalactosamine Is an Endocytic Receptor Expressed on Monocyte-derived Immature Dendritic Cells
J. Biol. Chem., May 31, 2002; 277(23): 20686 - 20693.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Bergeron, S. Champetier, Hélèn. LaRue, and Y. Fradet
MAUB Is a New Mucin Antigen Associated with Bladder Cancer
J. Biol. Chem., March 22, 1996; 271(12): 6933 - 6940.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1992 by the American Association for Cancer Research.